ライフサイエンスコーパス: oxcarbazepine

1 primidone to 34.3 per 1000 person-years for oxcarbazepine.

2 logical treatments include carbamazepine and oxcarbazepine.

3 phenytoin, and 1.16 (95% CI, 0.81-1.66) for oxcarbazepine.

4 phenytoin, and 0.71 (95% CI, 0.42-1.18) for oxcarbazepine.

5 7-1.09]), topiramate (0.86 [0.72-1.03]), and oxcarbazepine (0.92 [0.73-1.18]).

6 etiracetam, -0.06 (0.03) mug/L/mg (P = .01); oxcarbazepine, -0.14 (0.04) mug/L/mg (P < .001); oxcarba

7 ad a non-significant advantage compared with oxcarbazepine (1.15 [0.86-1.54]).

8 compared with placebo [adjusted mean change: oxcarbazepine, -10.90 (N=55); placebo, -9.79 (N=55)].

9 g/L/mg to 7.97 mug/L/mg; P = .03), 32.6% for oxcarbazepine (11.55 mug/L/mg to 7.79 mug/L/mg; P < .001

10 ine (3.1%; 95% CI, 2.5%-3.7%), 13 of 443 for oxcarbazepine (2.9%; 95% CI, 1.7%-5.0%), and 33 of 1325

11 responded to lamotrigine (56%), followed by oxcarbazepine (46%), duloxetine (30%), carbamazepine (26

12 7.79 mug/L/mg; P < .001), 30.6% for unbound oxcarbazepine (6.15 mug/L/mg to 4.27 mug/L/mg; P < .001)

13 Oxcarbazepine, a keto-analogue of carbamazepine, was rec

14 amazepine (AHR, 1.13; 95% CI, 0.85-1.50), or oxcarbazepine (AHR, 0.68; 95% CI, 0.44-1.05).

15 Finally, we found that oxcarbazepine and Huperzine A, a sodium channel blocker

16 For focal epilepsy, oxcarbazepine and lamotrigine are first-line therapy, wh

17 e of psychiatric adverse events for both the oxcarbazepine and placebo groups was higher than that re

18 erved in offspring exposed to levetiracetam, oxcarbazepine, and lamotrigine.

19 sts that the use of gabapentin, lamotrigine, oxcarbazepine, and tiagabine, compared with the use of t

20 antiepileptic drugs, such as carbamazepine, oxcarbazepine, and topiramate, enhances hepatic cytochro

21 ch as valproate, lamotrigine, carbamazepine, oxcarbazepine, antipsychotics, electroconvulsive therapy

22 Lamotrigine, gabapentin, topiramate, and oxcarbazepine are available for use as monotherapy in ma

23 Carbamazepine and oxcarbazepine are drugs of first choice for long-term tr

24 vidence that lamotrigine, carbamazepine, and oxcarbazepine are not associated with long-term behavior

25 Because carbamazepine and oxcarbazepine can enhance the sensitivity of renal tubul

26 Understanding the mechanisms by which oxcarbazepine can lead to a reduction of serum sodium le

27 cts titrated over 3 weeks to a maximum daily oxcarbazepine dose of 2,400mg.

28 er an acute water-load test performed before oxcarbazepine exposure and after maintenance on the medi

29 Before oxcarbazepine exposure, the percentage of water load exc

30 evetiracetam was superior to lamotrigine and oxcarbazepine for retention (P < 0.001); among second-li

31 racetam remained superior to lamotrigine and oxcarbazepine for retention (P < 0.001); among second-li

32 racetam remained superior to lamotrigine and oxcarbazepine for retention (P < 0.02); topiramate had t

33 vetiracetam and lamotrigine were superior to oxcarbazepine for seizure freedom (P < 0.001), and levet

34 th lamotrigine, levetiracetam, carbamazepin, oxcarbazepine, gapapentin, pregabalin, clonazepam, or ph

35 Eleven patients (19%) in the oxcarbazepine group discontinued the study because of ad

36 ported in at least 5% of the patients in the oxcarbazepine group with an incidence at least twice tha

37 with low bioavailability and solubility (eg, oxcarbazepine) had the greatest variability in BE.

38 , lamotrigine (HR, 1.84; 95% CI, 1.43-2.37), oxcarbazepine (HR, 2.07; 95% CI, 1.52-2.80), tiagabine (

39 er trial examined the efficacy and safety of oxcarbazepine in the treatment of bipolar disorder in ch

40 These findings indicate that oxcarbazepine-induced hyponatremia is not attributable t

41 Oxcarbazepine is not significantly superior to placebo i

42 he water load, suggesting that the effect of oxcarbazepine is physiological.

43 ine, lamotrigine+valproate, lithium, lithium+oxcarbazepine, lithium+valproate, olanzapine, paliperido

44 ouble-blinded, flexibly dosed treatment with oxcarbazepine (maximum dose 900-2400 mg/day) or placebo.

45 Oxcarbazepine (mean dose=1515 mg/day) did not significan

46 and new chemical C-H oxidation methods using oxcarbazepine, naproxen, and an early compound hit (phth

47 We also prioritised clemastine, lamotrigine, oxcarbazepine, nimodipine and flunarizine.

48 ssible mechanisms include a direct effect of oxcarbazepine on the renal collecting tubules or an enha

49 eive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate.

50 eive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate.

51 continuation of carbamazepine, lamotrigine, oxcarbazepine, or valproate with the risk of developing

52 continuation of carbamazepine, lamotrigine, oxcarbazepine, or valproate.

53 Carbamazepine (CBZ) and oxcarbazepine (OXC) are widely used anticonvulsants that

54 tive eiASMs (carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, primidone, rufi

55 um channel blocker treatment (carbamazepine, oxcarbazepine, phenytoin, lamotrigine or lacosamide) wit

56 Some patients treated with oxcarbazepine showed the development of hyponatremia, wh

57 After the intake of oxcarbazepine, the water load resulted in a reduction of

58 nd more variable comparing carbamazepine and oxcarbazepine to lamotrigine.

59 th rescue TDM of lamotrigine, levetiracetam, oxcarbazepine, topiramate, brivaracetam, zonisamide, or

60 rbazepine, -0.14 (0.04) mug/L/mg (P < .001); oxcarbazepine unbound, -0.11 (0.03) mug/L/mg (P < .001);

61 d more variable (5-year RD for initiation of oxcarbazepine vs lamotrigine, 0.29%; 95% CI, -0.12% to 0

62 exposure to lamotrigine, carbamazepine, and oxcarbazepine was not associated with an increased risk

63 Carbamazepine and oxcarbazepine were not immunosuppressive in lymphocyte-d

64 he sodium channel blockers carbamazepine and oxcarbazepine, which although effective are associated w